Arix Bioscience and Ipsen start cooperation on innovative therapies

| By | Drug Development, Ipsen, R&D
0
437

Arix Bioscience, a global healthcare and life science company supporting medical innovation, and Ipsen, a global specialty-driven biopharmaceutical company focused on innovation and specialty care, announced a strategic agreement to develop and commercialise innovative therapies.

Arix will provide Ipsen with access to its unique network of professional and scientific advisors, and the chance to invest in opportunities in Arix’s new and existing businesses. In return, Ipsen will contribute research, development and commercial expertise to the partnership. Arix and Ipsen will collaborate to identify opportunities and jointly create new companies focused primarily on the development and commercialisation of innovative therapies for patients.

Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: “This agreement brings together Ipsen’s deep expertise in drug development and commercialization with Arix’s proven capacity to identify new opportunities and build companies to develop innovative new therapies in areas of high unmet medical need.”

David Meek, Chief Executive Officer of Ipsen, added: “By building this relationship with Arix, we can benefit from Arix’s leading networks, advisors and businesses and can support these in turn with our R&D and commercialisation capabilities and expertise.”

SOURCE: ipsen
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.